Tracy Katz, MD
Dermatology · Houston, TXNPI 1578792776
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $80,602 of the $87,553 with a category attached, or 92.1%. Lumenis BE LTD accounts for 91.5% of it on its own, with 27 other manufacturers making up the rest. Among dermatology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $298.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lumenis BE LTD$80K
- Merz North America, Inc.$2K
- AbbVie$2K
- Galderma Laboratories, L.p.$813
- Almirall LLC$453
- Johnson & Johnson$453
- plus $2K from 22 others
Across 1 payment — averaging $918.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$918
What the payments were for
- Speaking & faculty fees$80,60292%
- Food & beverage$6,8198%
- Education$1320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lumenis BE LTD | 3 | $80,152 |
| Merz North America, Inc. | 16 | $1,748 |
| AbbVie(2 entities) | 83 | $1,533 |
| Galderma Laboratories, L.p. | 25 | $813 |
| Almirall LLC | 21 | $453 |
| Johnson & Johnson | 22 | $453 |
| Arcutis Biotherapeutics, Inc. | 13 | $302 |
| Mayne Pharma Commercial LLC | 13 | $270 |
| Pfizer | 11 | $206 |
| Amgen | 8 | $188 |
| LEO Pharma Inc. | 9 | $159 |
| Sun Pharmaceutical Industries Inc. | 8 | $148 |
| UCB, Inc. | 5 | $143 |
| Encore Dermatology Inc. | 13 | $130 |
| Novartis | 8 | $129 |
| Incyte Corporation | 7 | $125 |
| Regeneron Healthcare Solutions, Inc. | 4 | $110 |
| Verrica Pharmaceuticals Inc. | 5 | $99 |
| E.r. Squibb & Sons, L.L.C. | 4 | $83 |
| Dermira, Inc. | 3 | $76 |
| Sanofi | 2 | $59 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $48 |
| Lilly USA, LLC | 2 | $43 |
| GSK | 1 | $21 |
| Mylan Pharmaceuticals Inc. | 1 | $20 |
| VYNE Pharmaceuticals Inc. | 1 | $20 |
| Botanix SB Inc | 1 | $17 |
| Organon | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$87,553 in reported general payments places this provider in the 90th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 14 | $756 |
| Doxycycline Hyclate | 29 | $627 |
| Spironolactone | 14 | $239 |
| Ketoconazole | 14 | $178 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Houston
- Alpesh DesaiHouston$1.6M
- Geeta PatelHouston$575K
- Michael MigdenHouston$310K
- Catherine PapasakelariouHouston$289K
- Stephen MahoneyHouston$137K
- Edward LainAustin$2.5M
- William CragunSan Antonio$2.2M
- Craig TellerBellaire$1.3M
- Jennifer CatherDallas$1.3M
- Emily BeckerSan Antonio$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.